Unknown

Dataset Information

0

Paliperidone palmitate once-every-3-months in adults with early illness schizophrenia.


ABSTRACT: AIM:This post hoc analysis of a double-blind (DB), randomized, placebo-controlled, relapse-prevention study evaluated the effects of paliperidone palmitate once-every-3-months (PP3M) in a subpopulation of adults with early illness schizophrenia (duration ?5 years) from a clinical trial. METHODS:Patients received either PP3M or placebo every 3 months in the DB phase. The primary efficacy variable was time from randomization to first relapse. Symptom severity, patient functioning, and safety were also assessed. RESULTS:A total of 119 patients who entered the DB phase met the criteria for early illness schizophrenia (PP3M, n?=?62; placebo, n?=?57). PP3M significantly delayed time to relapse vs placebo (P?=?.035; hazard ratio, 3.08; 95% CI, 1.08-8.80). Symptomatic control and patient functioning were maintained in the PP3M group but significantly worsened in the placebo group. There were no unexpected tolerability findings. CONCLUSIONS:PP3M reduced relapse risk and maintained symptomatic and functional improvements compared with placebo in patients with early illness schizophrenia.

SUBMITTER: Bell Lynum KS 

PROVIDER: S-EPMC6585630 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Paliperidone palmitate once-every-3-months in adults with early illness schizophrenia.

Bell Lynum Karimah S KS   Turkoz Ibrahim I   Kim Edward E  

Early intervention in psychiatry 20180703 3


<h4>Aim</h4>This post hoc analysis of a double-blind (DB), randomized, placebo-controlled, relapse-prevention study evaluated the effects of paliperidone palmitate once-every-3-months (PP3M) in a subpopulation of adults with early illness schizophrenia (duration ≤5 years) from a clinical trial.<h4>Methods</h4>Patients received either PP3M or placebo every 3 months in the DB phase. The primary efficacy variable was time from randomization to first relapse. Symptom severity, patient functioning, a  ...[more]

Similar Datasets

| S-EPMC4898156 | biostudies-literature
| S-EPMC5380018 | biostudies-literature
| S-EPMC7061019 | biostudies-literature
| S-EPMC3431970 | biostudies-literature
| S-EPMC7028061 | biostudies-literature
| S-EPMC9440679 | biostudies-literature
| S-EPMC6603286 | biostudies-literature
| S-EPMC4550921 | biostudies-other
| S-EPMC10799459 | biostudies-literature
| S-EPMC3736921 | biostudies-literature